A detailed history of Ubs Group Ag transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Ubs Group Ag holds 7,016 shares of PRLD stock, worth $6,595. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,016
Previous 10,934 35.83%
Holding current value
$6,595
Previous $41,000 65.85%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.07 - $6.37 $8,110 - $24,957
-3,918 Reduced 35.83%
7,016 $14,000
Q2 2024

Aug 13, 2024

SELL
$3.32 - $5.63 $15,673 - $26,579
-4,721 Reduced 30.16%
10,934 $41,000
Q1 2024

May 13, 2024

SELL
$2.68 - $4.84 $11,304 - $20,415
-4,218 Reduced 21.22%
15,655 $74,000
Q4 2023

Feb 09, 2024

BUY
$1.69 - $4.37 $21,065 - $54,472
12,465 Added 168.26%
19,873 $84,000
Q3 2023

Nov 09, 2023

BUY
$2.74 - $4.79 $1,413 - $2,471
516 Added 7.49%
7,408 $22,000
Q2 2023

Aug 11, 2023

BUY
$4.45 - $8.12 $26,308 - $48,005
5,912 Added 603.27%
6,892 $31,000
Q1 2023

May 12, 2023

SELL
$4.58 - $7.34 $261 - $418
-57 Reduced 5.5%
980 $5,000
Q4 2022

Feb 08, 2023

BUY
$4.61 - $8.5 $4,467 - $8,236
969 Added 1425.0%
1,037 $6,000
Q3 2022

Nov 10, 2022

SELL
$5.0 - $8.82 $13,190 - $23,267
-2,638 Reduced 97.49%
68 $0
Q2 2022

Aug 10, 2022

BUY
$4.0 - $7.55 $10,092 - $19,048
2,523 Added 1378.69%
2,706 $14,000
Q1 2022

May 16, 2022

SELL
$6.9 - $13.22 $12,109 - $23,201
-1,755 Reduced 90.56%
183 $1,000
Q4 2021

Feb 14, 2022

SELL
$11.89 - $31.74 $416,899 - $1.11 Million
-35,063 Reduced 94.76%
1,938 $23,000
Q3 2021

Nov 15, 2021

BUY
$25.78 - $38.65 $758,782 - $1.14 Million
29,433 Added 388.91%
37,001 $1.16 Million
Q2 2021

Aug 13, 2021

SELL
$28.63 - $44.3 $422,807 - $654,222
-14,768 Reduced 66.12%
7,568 $216,000
Q1 2021

May 12, 2021

BUY
$39.27 - $91.68 $775,778 - $1.81 Million
19,755 Added 765.4%
22,336 $968,000
Q4 2020

Feb 11, 2021

BUY
$28.81 - $88.94 $33,361 - $102,992
1,158 Added 81.38%
2,581 $185,000
Q3 2020

Nov 12, 2020

BUY
$26.2 - $30.13 $37,282 - $42,874
1,423 New
1,423 $43,000

Others Institutions Holding PRLD

About Prelude Therapeutics Inc


  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $34.2M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.